Skip to main content

Table 6 Novel agents in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Study Agents Other agents Disease Dosage Clinical trails No Pts Response Reference
CPX-351
(liposomal cytarabine: daunorubicin at 5:1)
  Elderly untreated AML 100 u/m2 D1,3,5 Phase IIb 45 acceptable toxicity and comparable to standard regimen [9]
Voreloxin (anticancer quinolone derivative)   Elderly untreated AML 72 mg/m2 qw × 3 Phase II 105 CR/CRp: 47% [45]
Amonafide (AS1413) Cytarabine Secondary AML 600 mg/m2/d IV d1-5 Phase II 88 CR/CRi: 42% [46]
behenoylara-C Idarubicin
Etoposide
untreated AML 300-350 mg/m2
× 10d
Phase II 165 CR: 87% [47]
Lenalidomide Cytarabine, Daunorubicin 5q-AML/MDS 10 mg/d po d1-21 Phase I/II 18 CR/CRi: 47% [50]
Ribavirin Cytarabine AML    13 CR:7% [51]
ARRY-520 idarubicin refractory AML 0.8-5.6 mg/m2 IV Phase I 33 MTD: 4.5 mg/m2 [52]
AZD1152   relapsed AML 50 mg-1600 mg Phase I/II 64 MTD: 1200 mg [53]
AZD6244   AML 100 mg po bid Phase II 47 Feasible treatment [56]
Terameprocol   relapsed and refractory AML 1000-2200 mg iv, 3/w, ×2-3w Phase I/II 16 MTD: 1500 mg [57]
  1. Abbreviations: CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; MTD: maximal tolerated dose;